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ABSTRACT
Changes in the immune system induced by tyrosine kinase inhibitors (TKI) have been shown to
positively correlate with therapy responses in chronic myeloid leukemia (CML). However, only a few
longitudinal studies exist and no randomized comparisons between two TKIs have been reported.
Therefore, we prospectively analyzed the immune system of newly diagnosed CML patients treated
with imatinib (n = 20) or bosutinib (n = 13), that participated in the randomized BFORE trial
(NCT02130557). Comprehensive immunophenotyping, plasma protein profiling, and functional assays
to determine activation levels of T and NK cells were performed at diagnosis, 3, and 12 months after
therapy start. All results were correlated with clinical parameters such as Sokal risk and BCR-ABL load
measured according to IS%.
At diagnosis, low Sokal risk CML patients had a higher frequency of cytotoxic cells (CD8 +
T and NK cells), increased cytotoxic potential of NK cells and lower frequency of naïve and central
memory CD4 + T cells. Further, soluble plasma protein profile divided patients into two distinct
clusters with different disease burden at diagnosis. During treatment, BCR-ABL IS% correlated
with immunological parameters such as plasma proteins, together with different memory subsets
of CD4+ and CD8 + T cells. Interestingly, the proportion and cytotoxic potential of NK cells
together with several soluble proteins increased during imatinib treatment. In contrast, no major
immunological changes were observed during bosutinib treatment. In conclusion, imatinib and
bosutinib were shown to have differential effects on the immune system in this randomized
clinical trial. Increased number and function of NK cells were especially observed during imatinib
therapy.
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There are currently five approved tyrosine kinase inhibitors
(TKIs) for the treatment of chronic phase chronic myeloid
leukemia (CP CML). Imatinib was first launched approxi-
mately 15 years ago, soon followed by the second-generation
TKIs, dasatinib, nilotinib, and bosutinib, and last, the third-
generation TKI, ponatinib.1 All the TKIs, with the exception
of ponatinib, are now approved as first-line treatments in
CML.2,3 The advances in the treatment of CML with different
TKIs have led to a vast decrease in patients who are overall
unresponsive or intolerant to therapy, as they may be treated
with several different TKIs sequentially.4 Today, CP CML
patients are likely to have a normal life expectancy, but the
majority face a life-long exposure to TKIs. Recent evidence
shows, however, that up to half the patients who have
achieved an optimal therapy response are able to discontinue
their treatment without relapse, which may be partly due to
the immunological changes observed during the treatment.5,6
TKIs are not entirely selective for BCR-ABL1 kinase inhi-
bition because they also inhibit a variety of other kinases that
may ultimately cause off-target effects. Notably, the second-
generation inhibitors bosutinib and dasatinib both inhibit Src-
kinases, which are important mediators of T-cell function.7,8
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In contrast, imatinib and nilotinib have a much more narrow
inhibition profile.7 Earlier data from us and others have
shown that dasatinib, in particular, has significant effects on
the BCR-ABL-negative healthy immune cell compartment of
CML patients both in vivo and in vitro, 5,9–15 whereas the
immunomodulatory effects of imatinib have been previously
shown especially in CML (as reviewed by Zitvogel et al.)16 and
gastrointestinal stromal tumors and recently also in neuro-
blastoma .13,16–18 However, no systematic analysis of the
immunological effects of the other second-generation TKI
bosutinib inhibiting SRC family kinases at clinically relevant
concentrations has yet been performed. Therefore, we aimed
to characterize the immunological changes during frontline
bosutinib and imatinib treatments, and analyze how these
changes would correspond with the primary clinical para-
meters, such as the Sokal risk and BCR-ABL IS%, in order
to understand the overall effects on the immune system in CP
CML patients.
Results
CML patients with low Sokal risk score present a more
active immune system at diagnosis
In order to study the effects of disease burden on the immune
system, we first divided our CP CML cohort (n = 33) into three
groups based on their Sokal risk score at diagnosis: low (n = 11),
intermediate (n = 15), and high-risk (n = 6) (Tables 1 and 2). The
immune system before the start of treatment was studied by
extensive phenotyping, functional assays to measure the poten-
tial activity of both T and NK cells, and measuring 92 different
plasma analytes by a high-throughput, multiplex immunoassay.
The highest median percentage of the main cytotoxic NK cell
population (CD3negCD56+ CD16+) from the lymphocytes was
observed in the low (12.1%) and intermediate Sokal risk groups
(12.9%), compared to the high-risk patients (6.5%; p = .06 and
0.07) (Figure 1(a)). The low-risk patients had significantly less
CD3 + T cells from lymphocytes (68.6% vs. 76.6%; p = .002)
Table 1. Characteristics of bosutinib-treated patients (n = 13).
No Age at dg. Sex (f/m) Arm Sokal risk group BCR-ABL IS% at dg. BCR-ABL IS% at 3m
BCR-ABL
IS% at 12m
Bo1 46 f Bosutinib Inter. 107,8 3,1 0,029
Bo2 32 f Bosutinib High 16,9 0,008 neg
Bo3 30 m Bosutinib Low 82,0 1,51 0,0016
Bo4 42 f Bosutinib Inter. 99,6 21,36 switched to Im
Bo5 62 f Bosutinib High 77,9 20,04 switched to Im
Bo6 54 m Bosutinib Inter. 93,88 0,26 0,0086
Bo7 35 f Bosutinib Low 74,9 0,15 neg
Bo8 77 f Bosutinib Inter. 24,2 switched to Im switched to Im
Bo9 28 f Bosutinib Low 98,1 7,98 0,019
Bo10 30 m Bosutinib Low 19,6 0,20 discontinued
Bo11 60 f Bosutinib Inter. 92,5 16,9 0,012
Bo12 52 m Bosutinib Inter. 76,7 1,22 0,049
Bo13 62 f Bosutinib Low 79,0 discontinued discontinued
Median [range] 46
[28–77]









Abbreviations: dg, diagnosis; f, female; Im, Imatinib; Inter., intermediate; IS, international scale; m, male.
Table 2. Characteristics of imatinib-treated patients (n = 20).
No Age at dg. Sex (f/m) Arm Sokal risk group BCR-ABL IS% at dg. BCR-ABL IS% at 3m BCR-ABL IS% at 12m
Im1 30 f Imatinib Inter. 34,1 12,1 0,157
Im2 67 f Imatinib Inter. 79,7 5,0 0,019
Im3 59 f Imatinib High 27,1 2,4 0,497
Im4 47 m Imatinib Low 18,9 0,53 0,0068
Im5 55 f Imatinib Inter. 22,8 3,66 discontinued
Im6 62 m Imatinib Inter. 50,5 9,79 0,672
Im7 65 f Imatinib Inter. NA* NA* NA*
Im8 55 f Imatinib Low 92,6 23,14 0,363
Im9 58 f Imatinib High 93,3 discontinued discontinued
Im10 70 m Imatinib Inter. 65,2 5,13 0,013
Im11 43 m Imatinib Inter. 84,1 2,16 0,103
Im12 31 m Imatinib Inter. 20,8 2,91 0,038
Im13 81 m Imatinib NA** NA** NA** NA**
Im14 59 f Imatinib High 62,3 26,71 2,589
Im15 71 m Imatinib Inter. 63,7 41,4 0,009
Im16 44 m Imatinib Low 117,6 10,51 0,506
Im17 51 f Imatinib Low 85,2 8,48 0,074
Im18 73 m Imatinib High 12,6 1,97 0,133
Im19 75 m Imatinib Low 3,1 0,80 0,0078
Im20 51 m Imatinib Low 104,1 28,65 32,8
Median [range] 58
[30–81]









Abbreviations: dg, diagnosis; f, female; Inter, intermediate; IS, international scale; m, male, NA*, not available, atypical transcripts; NA** Not available, screening
failure.
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(Figure 1(b)). The low-risk patients also had the highest percentage
of CD8+T cells from theCD3+T cells (median 32.3%) compared
to high-risk patients (24.2%; p = .08) (Figure 1(c)). Consequently,
low-risk patients had less CD4 +T cells (median 59.8%) compared
to the intermediate (70.2%; p = .31) and high-risk patients (72.1%;
p = .04) (data not shown). Further, low-risk patients had signifi-
cantly less CD57 expressing CD8 + T cells (median 16.4%) com-
pared to the rest of the Sokal groups (intermediate 37.3%; p = .24
and high risk 58.8%; p = .02) (Figure 1(d)). When comparing the
memory status of T cells by expression of CCR7 and CD45RA, 19
we observed that the low-risk patients had significantly less naïve
CCR7+ CD45RA+ CD4 + T cells (median for low risk 0.5%, and
intermediate 2.7%; p = .018 and high risk 2.2%; p = .036) and
central memory CCR7+ CD45RAneg CD4 + T cells (median for
low risk 0.6%, and intermediate 2.3%; p = .016 and high risk 1.4%;
p = .052) (Figure 1(e,f)). No significant differences were observed
in the absolute numbers for CD3+, CD4+, and CD8 + T cells, and
CD3negCD56+ CD16+ NK cells (supplementary Figure 1).
We further analyzed the function of the NK cells from
a proportion of the patients (low n = 9, intermediate n = 9 and
high risk n = 5) by stimulating the cells with the target cell line
K562 and measuring the degranulation from CD107a/b expres-
sions. The low Sokal risk patients had more functional NK cells
(median 21.0%) at diagnosis when compared to the intermedi-
ate-risk (13.6%, p = .05) and high-risk patients (8.9%, p = .06)
(Figure 1(g)). Representative case of CD107 expression in
unstimulated and K562-stimulated NK cells is shown in supple-
mental Figure 2(a). Interestingly, the comparison of unstimulated
NK cells at diagnosis revealed a higher baseline degranulation in
the low-risk patients (supplemental Figure 2(b)).
The analysis of plasma proteins revealed a higher concen-
tration of TRAIL, a ligand that induces apoptosis, in low and
intermediate-risk Sokal patients in comparison to the high-
risk patients (p = .11 and 0.06; Figure 1(h)).
Correlation of immunological parameters with BCR-ABL
IS% at diagnosis and during treatment
To further evaluate the effects of disease burden on the immune
system, we next correlated the immunological parameters to
BCR-ABL at diagnosis, then at 3 and 12 months after therapy.
We performed a rank correlation between the BCR-ABL IS%
score (all patients combined) and characterized the immune
system with phenotyping, functional assays, and plasma cyto-
kine analyses. At diagnosis, both patient groups had similar
leukemic cell burden; the median BCR-ABL IS% was 79 in the
bosutinib and 75 in the imatinib group (Tables 1 and 2; p = .29).
After 3 and 12 months on treatment, bosutinib-treated patients
had better treatment responses with significantly lower BCR-
ABL levels (at 3 months 1.51 vs. 8.48, p = .046 and at 12 months
0.01042 vs. 0.103, p = .0069, Tables 1 and 2).
a b c d
e f g h
Figure 1. Low Sokal risk CML patients present a more active immune system. Effects of disease burden on the immune system were studied by first dividing the
patients (n = 33) into three groups (low, intermediate, and high risk) based on their Sokal score at diagnosis and then by performing phenotyping and functional
assays as well as measuring plasma proteins. Low and intermediate-risk patients had a higher percentage of NK cells (CD3negCD56+ CD16+) from lymphocytes than
high risk patients (a). The low-risk patients had also lower frequency of CD3 + T cells from lymphocytes (b), higher percentage of CD8+ from total T cells (c), and
a lower proportion of CD57 positive CD8 + T cells (d). Moreover, the low-risk patients had also the lowest frequency of naïve (e) and central memory CD4 + T cells (f).
Also, the degranulation of NK cells was highest in the low-risk patients after in vitro stimulation (g). Plasma protein measurements revealed that the highest
concentration of TRAIL in the plasma at diagnosis was also observed in the low-risk patients (h). TRAIL level is expressed as Normalized Protein eXpression (NPX)
values, an arbitrary unit on log2-scale. Non-parametric Wilcoxon signed-ranked test was performed to compute the differences among three groups and data are
presented as boxplots, including the median values for each parameter.
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At diagnosis, a significant negative correlation to the IS%
score was observed in CD45RA+ CD8+ and CD45RA+ CD4 +
T cells, Ki67+ CD8 + T cells and central memory CD8 +
T cells (Figure 2(a)), suggesting that patients with higher
tumor burden have more suppressed immune system at
diagnosis.
Interestingly, both at 3 and 12 months GrB+ CD56+ NK
cells showed significant negative correlation to disease burden
suggesting that cytotoxic NK cells are associated with better
treatment responses (lower BCR-ABL IS%). Moreover, posi-
tive correlation to the IS% score was observed cytokine-
producing CD4 + T cells at 3 months (representative case of
TNF-alpha and IFN-gamma production in unstimulated and
stimulated T cells are shown in supplemental Figure 3, patient
Im4, Table 2). Other immune cell populations correlated only
at 3- or 12-month time-points hindering definitive conclu-
sions to be drawn (Figure 2(a)).
From the plasma analysis (normalized with the values
from healthy controls), we found a positive correlation at
diagnostic IS% with only IL-10RA (Figure 2(b)). However,
at 3 months after the initiation of therapy, positive corre-
lations were observed with the following cytokines:
CXCL1, IL-10RA, CXCL5, Flt3L, CXCL6, CCL28,
CX3CL1, and ST1A1. At the 12-month time-point, posi-
tive correlations between the IS% and CCL4, TNF-α,
Flt3L, CXCL10, and CX3CL1 were detected (Figure 2(b)).
a b
c
Figure 2. BCR-ABL burden correlates with immunological parameters during treatment time. Spearman rank correlation analysis revealed several significant hits
when comparing BCR-ABL IS% at diagnosis, then 3 and 12 months after treatment start with multiple phenotyping parameters (a) as well at plasma proteins (b). The scale
indicates correlation coefficient values: positive correlations are observed with red color and negative with blue color. Nonsignificant results are marked with an X. Individual
correlation plots with regression were analyzed for CX3CL1, IL-10RA, and Flt3L at baseline, 3 months and 12 months (c). One outlier (abnormally high BCR-ABL IS%) was
removed from the analysis. Bosutinib-treated patients are presented in the figures in green and imatinib-treated patients in red. Protein levels are expressed as Normalized
Protein eXpression (NPX) values, an arbitrary unit on log2-scale. Regulatory T cells were gated as CD45+ CD3+ CD4+ CD25high FoxP3+, memory subsets of T cells were
defined by expression of CCR7 and CD45RA, and cytokine-producing T cells refer to TNF-alpha and interferon-gamma-producing CD4 + T cells after in vitro-stimulation.
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To further study the link between leukemic cells and
cytokines, we next performed individual correlation plots
with the BCR-ABL IS% for the most significant findings
from the rank correlation analysis, namely CX3CL1, IL-
10RA and Flt3L (Figure 2(c)).
The frequency and cytotoxic potential of NK cells increase
during imatinib treatment
As NK cells are indicated to have a role in positive therapy
response to imatinib and dasatinib, 5,6,20,21 we next studied
the evolution of the cells during the two treatments by
phenotyping the NK cells and performing a degranulation
assay from the pre-treated and follow-up samples (3 and
12 months after initiation of treatment).
During imatinib treatment, the median proportion of CD56
+ CD16+ NK cells drastically increased (dg 3.9% vs. 3 months
9.9% p < .0001; vs 12 months 13.8% p = .0003). In contrast, no
significant changes were observed in the NK cells during bosu-
tinib treatment (dg 4.6%, 3 months 8.5%, 12 months 5.8%)
(Figure 3(a)). The cytotoxic potential of the NK cells, as mea-
sured by the expression of the degranulation marker CD107ab
in NK cells after stimulation with target cell line K562, signifi-
cantly increased after the start of imatinib treatment when
compared to the samples from diagnosis (median at dg 16.9%
vs. 3 months 29%, p = .0017; vs. 12 months 25.1%, p = .03)
(Figure 3(b,c)). No significant changes were observed during
bosutinib treatment (median at dg 22.8%, 3 months 16%, 12
months 34.9%). Representative case (Im3 in Table 2) of CD107
expression in unstimulated NK cells and K562-stimulated cells
is shown in supplemental Figure 2(a).
a b
c
Figure 3. Imatinib therapy increases the proportion and function of NK cells. NK cells were characterized by flow analysis and functional assays. Imatinib-
treatment significantly increases the proportion of NK cells from lymphocytes (a), as well as increase their responsiveness to K562-stimulation measured by
degranulation (b-c). Non-parametric Wilcoxon signed-ranked test was performed to find the difference in functional assay at different timepoint and data are
presented as boxplots.
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Plasma cytokine profile changes during imatinib
treatment
We next studied the changes in the soluble plasma proteins
and receptors in both treatment arms. Plasma samples from 8
imatinib- and 8 bosutinib-treated patients (all time-points)
and 10 healthy volunteers (6 females, 4 males, mean age
51.7 years) were analyzed using the Proseek® Multiplex
Inflammation immunoassay. Protein levels were expressed as
Normalized Protein eXpression (NPX) values, an arbitrary
unit on log2-scale.
At diagnosis, the patients had significantly higher
amounts of uPA (p = .0001), OSM (p = .00004), CD5
(p = .0002) and Flt3L (p = .03) compared to the healthy
controls (Table 3). While comparing the patient groups
and healthy controls, we observed that at 3 months,
imatinib significantly increased the amount of soluble
CXC3L1 (p = .007 compared to BO, p = .3 compared to
healthy). CX3CL1 continued to increase in imatinib
patients after 12 months of treatment (p = .01 compared
to BO, p = .07 compared to healthy). At diagnosis,
CX3CL1 levels were similar in the imatinib and bosutinib
groups (p = .80). In contrast, MCP-1 was slightly higher
at diagnosis in those patients who started on imatinib
treatment (median for imatinib 586.7 and for bosutinib
370.4, p = .10), and although MCP-1 levels increased
during both treatments, imatinib patients had still higher
levels at 3 months (p = .01 compared to BO, p = .01
compared to healthy) and at 12 months (p = .02 com-
pared to BO, p = .004 compared to healthy). Also,
TWEAK increased during both TKIs, with a steeper rise
during imatinib (at 3 months; p = .02 compared to BO,
p = .01 compared to healthy; at 12 months p = .16
compared to BO, p = .006 compared to healthy) treat-
ment. Similar results were observed with TRAIL (at 3
months; p = .04 compared to BO, p = .3 compared to
healthy; at 12 months p = .28 compared to BO, p = .08
compared to healthy) (Figure 4(a,b), Table 3, supplemen-
tal Figure 4). No differences at diagnosis were observed
for TWEAK and TRAIL when comparing the two patient
cohorts (p = .44 and 0.50).
Unsupervised clustering reveals distinct patient subsets
Different immune cell subclasses were clustered with unsu-
pervised hierarchical clustering to detect specific cell pheno-
types that associate with each other or with clinical factors
such as Sokal risk score, BCR-ABL IS% and study drug. All
data were normalized to diagnosis median values, in order to
visualize treatment-induced changes for each parameter.
At diagnosis, three distinct patient subgroups were
formed. Interestingly, the majority of low Sokal risk patients
clustered based on the low levels of terminally differentiated
effector CD8 + T cells, CD57+ CD8 + T cells (same as seen
in Figure 1(d)) and GrB+ CD8 + T cells (highlighted in
Figure 5). The same sets of CD8 + T cells clustered together
also at 3 and 12-month time-points. At 12 months, a cluster
including mostly (6/7) imatinib-treated patients was formed
based on the increased amount of the same CD8 + T cell
populations (highlighted in Figure 5). In addition, one
patient who was randomized to bosutinib arm but switched
to imatinib due to side-effects already before the 3-month
time-point was in the same cluster with the imatinib patients
(Bo8, marked with an asterisk in the annotation).
Same unsupervised clustering analysis, with 3 m and
12 m results normalized to diagnosis median values, was per-
formed with the plasma proteins at each timepoint. Notably,
cytokine profiles at diagnosis divided patients into two distinct
subgroups (Figure 6). Interestingly, the median BCR-ABL IS%
clearly differed between the two clusters at diagnosis (34.1 vs.
80.4). The cluster with higher BCR-ABL IS% levels had
increased amount of several different cytokines. At 12 months,
a distinct cluster of 10 patients was formed by 6 imatinib-
treated patients and two bosutinib-treated patients who had
switched to imatinib before the sampling (marked with asterisk
in the annotation in Figure 6). In addition, a group of soluble
plasma proteins clearly decreased after TKI start, namely CD5,
CD6, CD244, OSM, IL-10RA, IL-4, and TGF-alpha (marked
with blue arrows). In contrast, CCL28, SCF, TWEAK, CX3CL1,
IL-12B, and CCL25 (marked with red arrows) markedly
increased after TKI start (Figure 6).
Normal blood counts are achieved faster in
bosutinib-treated patients
Complete blood counts (percentages and absolute counts) were
compared between the two groups of patients at diagnosis, and
then at 3 and 12 months. No differences were observed in
between the groups at diagnosis, but at 3 months after therapy
start, bosutinib-treated patients had significantly higher abso-
lute numbers of leukocytes (p = .009), monocytes (p = .001),
neutrophils (p = .013) and platelets (p = .041) (Figure 7(a,b)),
whereas in some imatinib-treated patients the blood counts
were below the lower normal limit. Further at 12 months, the
leukocytes (p = .014), monocytes (p = .032) and neutrophils (p =
.022) were still significantly higher in the bosutinib group
(Figure 7(a,c)). No significant differences were observed in the
percentage or absolute counts of lymphocytes between the two
groups at either time-point (Figure 7(a)).
No changes were observed in the blood cell counts after
imatinib or bosutinib intake
The second-generation TKI, dasatinib, is known to induce
a rapid mobilization of lymphocytes to the peripheral blood
after drug intake.22 In order to study whether similar changes
would occur after imatinib or bosutinib intake, differential
blood counts were taken before and after 2 h of drug intake at
3- and 12-month time-points. In contrast to what was
observed in dasatinib-treated CML patients, no significant
changes were observed in the hemoglobin and the absolute
blood cell counts (leukocytes, erythrocytes, platelets, neutro-
phils, eosinophils, basophils or lymphocytes; supplemental
Figure 5). A significant increase was observed only in the
absolute monocyte counts (p = .027) at 3 months, and abso-
lute neutrophil counts (p = .0029) at 12 months after imatinib
admission (supplemental Figure 5).



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In principle, the immunological off-target effects of TKIs may
improve or impair the overall therapy outcome in CML
patients.23 The immune system, notably NK cells, has recently
been linked with successful treatment discontinuation.5,6,20,21
Therefore, several groups have lately attempted to understand
the immunological effects of TKIs in CML patients and their
impact on therapy responses. Especially, the SRC family of
kinases and other signaling pathways involved in cellular
activity of the immune system may play an important role
for secondary, immune-mediated effects of TKIs. Still, no
longitudinal studies have been performed to characterize the
immunomodulatory effects of first-line imatinib and bosuti-
nib in CP CML patients and how these changes correlate with
the remaining disease burden.
Two large phase III clinical trials, BELA (NCT00574873)
and BFORE (NCT02130557), have recently shown that bosu-
tinib is superior to imatinib in the first-line setting regarding
MMR rate at 12 months. Also, the complete cytogenetic
response rate at 12 months was significantly higher in the
bosutinib arms.24–26 These results are likely to be explained by
bosutinib´s higher activity against BCR-ABL and various
imatinib-resistant mutations.27 Bosutinib also has a wider
TK inhibitory profile than imatinib and thus more resembles
dasatinib, another second-generation TKI, in the sense that
for example, both inhibit the SRC kinase family.7,8
Interestingly, previous reports from our group and others
have shown significant immunomodulatory effects of
dasatinib.5,9–15,22 With this in mind, it is surprising that we
did not detect immunomodulatory effects in the bosutinib-
treated CML patients. In contrast, we observed that imatinib
treatment induced multiple immunological changes. As seen
in our study cohort as well as in the clinical trials, imatinib
treatment resulted in slower therapy responses and recovery
of the bone marrow, while bosutinib-treated patients mostly
achieved quicker therapy responses and faster regain of nor-
mal bone marrow functions. We are not able to exclude the
possibility that because bosutinib causes faster therapy
responses, there is no need for the immune system to activate
and clear remaining leukemic cells. In contrast, slower ther-
apy responses induced by imatinib could leave time for the
immune system to act after the initial immune suppression
observed at diagnosis is reverted.28 However, although dasa-
tinib induces a more rapid molecular response than imatinib,
significant immunological changes are observed during the
treatment.10 Therefore, it is also possible that imatinib has
direct immunological effects in CML similarly as shown in
gastrointestinal stromal tumors and neuroblastoma
patients.13,17,29
The initial fraction of leukemic stem cells at diagnosis is
known to have an impact on the overall therapy outcome, 30,31
but also on the immune system, causing significant malfunction
and suppression of the lymphocytes in CML patients.28,32–34
High Sokal risk CML patients have also been reported to have
higher numbers of myeloid-derived suppressor and PD1-
expressing CD8 + T cells.35 In accordance, we show here, that
patients with low and intermediate Sokal risk scores have more
active immune systems compared to those in the high-risk
category. This was particularly true for NK cells, which were
Figure 4. Differences of plasma protein at diagnosis and during TKI therapy. A p-value heatmap presenting significant differences between imatinib- and
bosutinib-treated patients’ plasma proteins (a). Imatinib-treated patients have a significant increase in MCP-1, CX3CL1. TWEAK and TRAIL at both 3-month and 12-
month time-points (b). Non-parametric Wilcoxon signed-ranked test was performed to compare differences between treatments and data are presented as boxplots.
Protein levels are expressed as Normalized Protein eXpression (NPX) values, an arbitrary unit on log2-scale.
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more frequent and also had a superior cytotoxic potential in the
low risk compared to the high-risk patients. Interestingly, recent
papers published by us and others have described an important
role for NK cells in achieving a deep molecular response and the
successful discontinuation of imatinib treatment.5,6,21,36 Ilander
et al. have shown that the proportion of NK cells was associated
with molecular relapse-free survival as patients with a higher
NK-cell percentage at the time of drug discontinuation had
a better probability of staying in remission. In addition,
Hughes et al. have recently reported that the quantitative and
functional defects of NK cells were observed at diagnosis, and
later, those patients who were in MMR and MR4.5 had acquired
more mature, cytolytic CD57+ CD62L-NK cell.36 Interestingly,
our present results show that both the percentage and the cyto-
toxic potential of the NK cells increased especially in the imati-
nib-treated patients, while bosutinib did not significantly affect
the NK-cell frequency or their function.
Cytokines are small proteins that are important for cell-cell
signaling and therefore, they represent useful readouts to
study changes in the immune system. In our CML cohort,
Figure 5. Unsupervised hierarchical clustering of immune cell subsets. Flow cytometry data for each timepoint were normalized to diagnosis median values and
heatmap was drawn based on Euclidean distance and unsupervised hierarchical clustering methods for each timepoint independently. Annotations were added for
Sokal risk at diagnosis, BCR-ABL IS% at each timepoint and study drug. Low Sokal risk patients at diagnosis clustered based on terminally differentiated effector CD8
+ T cells, CD57+ CD8 + T cells and GrB+ CD8 + T cells, which are highlighted in each heatmap. At 12-month time-point, the majority of imatinib-treated patients
cluster based on their T and NK cells phenotypes. Patients who started on bosutinib and switched to imatinib treatment during the 12-month follow up are marked
with an asterisk.
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we found that imatinib treatment led to elevated levels of
several soluble proteins in the plasma, whereas bosutinib
had minor effects. The most drastic differences between the
two patient groups were observed at 3 months. TRAIL,
TWEAK, CX3CL1, and MCP1 were significantly increased
during imatinib treatment. These plasma proteins are either
key players in cytotoxic pathways or function as chemoattrac-
tants for T cells among other cell types. Inflammatory cyto-
kines belonging to tumor necrosis factor (TNF) family, such
as TRAIL and TWEAK, are able to induce apoptosis in cancer
cells while exhibiting little or no toxicity in normal cells.37
Moreover, members of the TNF superfamily provide
a communication complex that is essential in synchronizing
multiple cell types into an effective host defense system
against malignant cells. These pathways differentiate both
innate and adaptive immune cells, and modulate stromal
cells into microenvironments that are conducive to host
defenses.38
Chemokines on the other hand induce chemotaxis in
responsive cells. We observed that CX3CL1 levels in particular
increased during imatinib treatment. CX3CL1 and its cognate
receptor CX3CR1 are involved in the recruitment of
leukocytes to the inflamed vasculature.39 CXC3L1 also
induces active migration of NK cells and by blocking the
CX3CL1/CXCR3 pathway it has been shown that the NK
cells no longer were able to clear the cancer cells in a mouse
tumor model.40 We conclude that these elevated cytokine
levels reflect an active immune system in the imatinib-
treated patients, affecting mainly the NK cells, and this is
also observed as an increased NK-cell percentage in these
patients. Moreover, our analysis revealed that leukemic cell
burden (as reflected by BCR-ABL IS%) during the treatment
time correlated positively with several plasma proteins such as
CCL4, CXCL1, CXCL5, CXCL6, CXCL10, CCL28, CX3CL1,
IL-10RA, Flt3L, ST1A1, and TNF.
In conclusion, the disease burden, including both Sokal risk at
diagnosis and BCR-ABL IS% during treatment, correlates with
multiple immunological factors, providing further insight into
the role of the immune system in CML. In addition, we observed
that imatinib treatment generated amore active immune system,
which correlated with the BCR-ABL IS%. In contrast, no clear
immunomodulatory effects were detected during bosutinib
treatment, despite the wide kinase inhibition profile of the
drug. We conclude that the immune system in CML patients
Figure 6. CML patients with high BCR-ABL IS% at diagnosis have distinct soluble plasma protein and receptor profile. Soluble plasma proteins were
calculated as NPX values at diagnosis and after therapy start. All data were normalized to baseline median values, in order to visualize treatment-induced changes in
each parameter. Heatmap analysis was performed including Euclidean distance and unsupervised hierarchical clustering methods for each timepoint independently,
and annotations were added for Sokal risk at diagnosis, BCR-ABL IS% at each timepoint and study drug. At diagnosis, two clusters with different BCR-ABL IS%
(median values 34.1 and 80.4) are observed with distinctive plasma protein profiles. After the therapy start, a group of soluble proteins and receptors clearly
decreased after TKI start, namely CD5, CD6, CD244, OSM, IL-10RA, IL-4, and TGF-alpha (marked with blue arrows). On the contrary, CCL28, SCF, TWEAK, CX3CL1, IL-
12B, and CCL25 (marked with red arrows) prominently increased after TKI start. Patients who started on bosutinib and switched to imatinib treatment during the 12-
month follow up are marked with an asterisk.
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with a low disease burden is more active and has a higher
functional capacity than in patients with a higher disease load.
Patients and methods
Study patients and samples
Newly diagnosed CP CML patients were enrolled in the BFORE
clinical trial (NCT02130557). Peripheral blood samples were
obtained from imatinib- (n = 20) and bosutinib-treated (n = 13)
patients at diagnosis (dg), as well as 3 and 12months after the start
of TKI therapy. Moreover, differential blood counts were taken
before and 2-h post drug intake at 3 and 12months to examine the
direct effects of the drug intake on lymphocyte counts.22
Peripheral blood mononuclear cells (PB MNCs) from all patients
and healthy controls were separated by Ficoll-Paque gradient
centrifugation (GE Healthcare, Buckingham, UK) and were
freshly used or stored as live vials at −150°C.
All patients and healthy controls gave a written informed
consent and the study was approved by the ethical committees
of each local university hospital. The study was conducted in
accordance with the Declaration of Helsinki.
Phenotyping
PBMNC were isolated with Ficoll from fresh blood and the cells
were immediately stained for 15min with surface markers (CD3,
CD4, CD8, CD14 (Invitrogen), CD16, CD19 (Invitrogen),
CD25, CD27, CD38, CD45, CD45RA, CD56, CD57, CCR7
(RnD), HLA-DR, NKG2D, and PD1). Intracellular stains using
FoxP3 (eBioscience) and Ki-67 antibodies were performed after
permeabilizing the cells with the Transcription Factor Staining
Buffer Set (eBioscience). A total of 50 000 lymphocytes were
acquired with the FACS Verse and analyzed with FlowJo
(Version 10.0.8r1, TreeStar) software. Dead cells were removed
from analysis from SSC vs FSC and CD45 scatter. All antibodies
were purchased from BD Biosciences (BD Biosciences, San
Diego, CA, USA) unless mentioned otherwise.
NK-cell degranulation assay
Thawed PB MNCs were stimulated with the target cell line
K562 at a 10:1 ratio. PB MNCs without target cells were used
as negative controls. Cells were incubated for 6 h in the
presence of antibodies containing degranulation markers,
CD107a and CD107b. All cells were stained with CD45,
CD3, CD16, and CD56. 50,000 CD45+ lymphocytes were
acquired with FACS Verse and analyzed with FlowJo.
Activation of T-cells
Thawed PB MNCs were stimulated with anti-CD3 (2.5 μg/
ml), co-stimulatory anti-CD28 (1 μg/ml), anti-CD49d (0.5 μg/
ml) (BD Biosciences), and incubated for 6 h at +37°C. PB
MNCs without stimulation were used as controls. GolgiStop
(BD Biosciences) was added to each well. After the incuba-
tion, cells were stained with the following antibodies: CD45,
CD3, CD4, CD8. Subsequently, cells were permeabilized and
fixed according to the Cytofix Cytoperm (BD Biosciences) kit
a b
c
Figure 7. Normal blood cell values are faster re-established during bosutinib-treatment. A p-value heatmap presenting significant differences between
imatinib- and bosutinib-treated patients’ complete blood counts (a). At diagnosis, no differences were observed between the two groups of patients. Three months
after therapy start, bosutinib-patients have higher absolute numbers of neutrophils, monocytes, platelets, and leukocytes (b). The same differences were observed
also after 12 months of treatment (c). Non-parametric Wilcoxon signed-ranked test was performed to compare differences between treatments and data are
presented as boxplots, showing the median value of each parameter.
ONCOIMMUNOLOGY e1638210-11
protocol. Intracellular stains were carried out with Granzyme
B, and the cytokines IFN-γ and TNF-α, whereby 50 000
CD45+ lymphocytes were analyzed with FACS Verse.
Soluble plasma protein and receptor analysis by
multiplex immunoassay
ACD plasma samples from 8 imatinib-treated, 8 bosutinib-treated
patients (all time-points), and 10 healthy volunteers (6 females, 4
males, mean age 51.7 years) were analyzed using the Proseek®
Multiplex Inflammation immunoassay. Proseek® is a high-
throughput, multiplex immunoassay that enables the analysis of
92 inflammation-related protein biomarkers simultaneously
(Proseek Multiplex CVD, Olink Bioscience, Uppsala, Sweden).
Protein levels were expressed as Normalized Protein eXpression
(NPX) values, an arbitrary unit on log2-scale.
Statistical analysis
For heatmaps, in the case of plasma protein data, the values
measured in the patients were normalized using the plasma
protein levels in healthy controls and scaled between −1 and
+1. The Euclidean distance and complete clustering methods
were used for the heatmap of both flow cytometry results and
plasma protein data heatmap. The differences between the
groups were analyzed using the non-parametric Wilcoxon
signed-ranked test. The correlation between the data sets
was computed using the Spearman rank correlation method.
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